224 related articles for article (PubMed ID: 34747302)
1. 4CMenB vaccine and its role in preventing transmission and inducing herd immunity.
McMillan M; Marshall HS; Richmond P
Expert Rev Vaccines; 2022 Jan; 21(1):103-114. PubMed ID: 34747302
[TBL] [Abstract][Full Text] [Related]
2. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
[TBL] [Abstract][Full Text] [Related]
3. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA
Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520
[TBL] [Abstract][Full Text] [Related]
4. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial.
Read RC; Baxter D; Chadwick DR; Faust SN; Finn A; Gordon SB; Heath PT; Lewis DJ; Pollard AJ; Turner DP; Bazaz R; Ganguli A; Havelock T; Neal KR; Okike IO; Morales-Aza B; Patel K; Snape MD; Williams J; Gilchrist S; Gray SJ; Maiden MC; Toneatto D; Wang H; McCarthy M; Dull PM; Borrow R
Lancet; 2014 Dec; 384(9960):2123-31. PubMed ID: 25145775
[TBL] [Abstract][Full Text] [Related]
5. B Part of It School Leaver Study: A Repeat Cross-Sectional Study to Assess the Impact of Increasing Coverage With Meningococcal B (4CMenB) Vaccine on Carriage of Neisseria meningitidis.
McMillan M; Koehler AP; Lawrence A; Sullivan TR; Bednarz J; MacLennan JM; Maiden MCJ; Ladhani SN; Ramsay ME; Trotter C; Borrow R; Finn A; Kahler CM; Whelan J; Vadivelu K; Richmond PC; Marshall HS
J Infect Dis; 2022 Feb; 225(4):637-649. PubMed ID: 34487174
[TBL] [Abstract][Full Text] [Related]
6. Exploiting Real-Time Genomic Surveillance Data To Assess 4CMenB Meningococcal Vaccine Performance in Scotland, 2015 to 2022.
Rodrigues CMC; MacDonald L; Ure R; Smith A; Cameron JC; Maiden MCJ
mBio; 2023 Apr; 14(2):e0049923. PubMed ID: 37036356
[TBL] [Abstract][Full Text] [Related]
7. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B
Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D
mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218
[No Abstract] [Full Text] [Related]
8. Effectiveness of Meningococcal Vaccines at Reducing Invasive Meningococcal Disease and Pharyngeal Neisseria meningitidis Carriage: A Systematic Review and Meta-analysis.
McMillan M; Chandrakumar A; Wang HLR; Clarke M; Sullivan TR; Andrews RM; Ramsay M; Marshall HS
Clin Infect Dis; 2021 Aug; 73(3):e609-e619. PubMed ID: 33212510
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive review of clinical and real-world safety data for the four-component serogroup B meningococcal vaccine (4CMenB).
Marshall GS; Abbing-Karahagopian V; Marshall HS; Cenci S; Conway JH; Occhipinti E; Bekkat-Berkani R; Banzhoff A; Sohn WY
Expert Rev Vaccines; 2023; 22(1):530-544. PubMed ID: 37278390
[TBL] [Abstract][Full Text] [Related]
10. Meningococcal B Vaccine and Meningococcal Carriage in Adolescents in Australia.
Marshall HS; McMillan M; Koehler AP; Lawrence A; Sullivan TR; MacLennan JM; Maiden MCJ; Ladhani SN; Ramsay ME; Trotter C; Borrow R; Finn A; Kahler CM; Whelan J; Vadivelu K; Richmond P
N Engl J Med; 2020 Jan; 382(4):318-327. PubMed ID: 31971677
[TBL] [Abstract][Full Text] [Related]
11. Discordant Effects of Licensed Meningococcal Serogroup B Vaccination on Invasive Disease and Nasal Colonization in a Humanized Mouse Model.
Buckwalter CM; Currie EG; Tsang RSW; Gray-Owen SD
J Infect Dis; 2017 May; 215(10):1590-1598. PubMed ID: 28368526
[TBL] [Abstract][Full Text] [Related]
12. Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: An application to England.
Beck E; Klint J; Garcia S; Abbing V; Abitbol V; Akerborg O; Argante L; Bekkat-Berkani R; Hogea C; Neine M; Vadivelu K; Whelan J; Meszaros K
Vaccine; 2020 Nov; 38(47):7558-7568. PubMed ID: 32807531
[TBL] [Abstract][Full Text] [Related]
13. Can we control all-cause meningococcal disease in Europe?
Sadarangani M; Pollard AJ
Clin Microbiol Infect; 2016 Dec; 22 Suppl 5():S103-S112. PubMed ID: 27129415
[TBL] [Abstract][Full Text] [Related]
14. Impact of Meningococcal B Vaccine on Invasive Meningococcal Disease in Adolescents.
McMillan M; Wang B; Koehler AP; Sullivan TR; Marshall HS
Clin Infect Dis; 2021 Jul; 73(1):e233-e237. PubMed ID: 33587122
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of a Meningococcal Group B Vaccine (4CMenB) in Children.
Castilla J; García Cenoz M; Abad R; Sánchez-Cambronero L; Lorusso N; Izquierdo C; Cañellas Llabrés S; Roig J; Malvar A; González Carril F; Boone ALD; Pérez Martín J; Rodríguez Recio MJ; Galmés A; Caballero A; García Rojas A; Juanas F; Nieto M; Viloria Raymundo LJ; Martínez Ochoa E; Rivas AI; Castrillejo D; Moreno Pérez D; Martínez A; Borràs E; Sánchez Gómez A; Pastor E; Nartallo V; Arteagoitia JM; Álvarez-Fernández B; García Pina R; Fernández Arribas S; Vanrell J; García Hernández S; Mendoza RM; Méndez M; López-Tercero MM; Fernández-Rodríguez Á; Blanco Á; Carrillo de Albornoz FJ; Ruiz Olivares J; Ruiz-Montero R; Limia A; Navarro-Alonso JA; Vázquez JA; Barricarte A
N Engl J Med; 2023 Feb; 388(5):427-438. PubMed ID: 36724329
[TBL] [Abstract][Full Text] [Related]
16. Control of invasive meningococcal disease: is it achievable?
Marshall H; Wang B; Wesselingh S; Snape M; Pollard AJ
Int J Evid Based Healthc; 2016 Mar; 14(1):3-14. PubMed ID: 26126001
[TBL] [Abstract][Full Text] [Related]
17. Real-world implementation of 4-component meningococcal serogroup B vaccine (4CMenB): implications for clinical practices.
Sohn WY; Tahrat H; Novy P; Bekkat-Berkani R
Expert Rev Vaccines; 2022 Mar; 21(3):325-335. PubMed ID: 35068299
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of co-administered meningococcal serogroup B (4CMenB) vaccine: A literature review.
Abitbol V; Sohn WY; Horn M; Safadi MAP
Hum Vaccin Immunother; 2023 Aug; 19(2):2245705. PubMed ID: 37642229
[TBL] [Abstract][Full Text] [Related]
19. A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine.
Read RC; Dull P; Bai X; Nolan K; Findlow J; Bazaz R; Kleinschmidt A; McCarthy M; Wang H; Toneatto D; Borrow R
Vaccine; 2017 Jan; 35(3):427-434. PubMed ID: 27912986
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination.
Martinón-Torres F; Banzhoff A; Azzari C; De Wals P; Marlow R; Marshall H; Pizza M; Rappuoli R; Bekkat-Berkani R
J Infect; 2021 Jul; 83(1):17-26. PubMed ID: 33933528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
